Shots:
- Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD (formerly OXB-102) to treat mod. to sev. PD based on Oxford’s LentiVector platform
- Axovant is conducting a P-II SUNRISE-PD trial with AXO-Lenti-PD while the dosing of all patients in the second cohort is completed with 6mos. safety and efficacy data, expected in the Q4’20. The CSA follows WW license agreement signed b/w the companies in Jun’2018 for AXO-Lenti-PD
- Oxford expects to manufacture AXO-Lenti-PD in its commercial-scale GMP manufacturing facilities including Oxbox in the UK, and in other facilities, as required to ensure the security of supply
Click here to read full press release/ article | Ref: Oxford Biomedica | Image: Oxford Biomedica
